News Article | January 6, 2017
London has breached its annual air pollution limits just five days into 2017, a “shameful reminder of the severity of London’s air pollution”, according to campaigners. By law, hourly levels of toxic nitrogen dioxide must not be more than 200 micrograms per cubic metre (µg/m3) more than 18 times in a whole year, but late on Thursday this limit was broken on Brixton Road in Lambeth. Many other sites across the capital will go on to break the annual limit and Putney High Street exceeded the hourly limit over 1,200 times in 2016. Oxford Street, Kings Road in Chelsea and the Strand are other known pollution hotspots. NO2 pollution, which is produced largely by diesel vehicles, causes 5,900 early deaths every year in London. Most air quality zones across the country break legal limits and the crisis was called a “public health emergency” by MPs in April. This week scientists said that one in 10 cases of Alzheimer’s in people living near busy roads could be linked to air pollution. The mayor of London, Sadiq Khan, has pledged new measures and to double funding to £875m over five years to tackle the problem. But the UK government’s national plans have twice been ruled illegal in the past two years and it has been sent back to the drawing board to develop a third strategy. Alan Andrews, a lawyer at ClientEarth – the group that successfully sued the government – said: “This is another shameful reminder of the severity of London’s air pollution and shows why the mayor has rightly made tackling it a top priority. It is absolutely essential that he now delivers on his promises and that the national government back him to the hilt.” Andrews, who lives in Brixton, said Khan had promised an expanded ultra-low emission zone in 2019, which limits polluting vehicles, and to deploy the cleanest buses on the most polluted roads. “While these are vital steps in the right direction, we can’t wait another three years for action,” Andrews said. “We need immediate action to cut pollution in the short-term and protect Londoners’ health during these pollution spikes.” In December, Khan issued air pollution alerts at bus stops, tube stations and roadsides due to high levels. A spokesman for the mayor said: “The Brixton Road [breach] underscores why urgent action is needed to improve air quality across London.” He said Khan would shortly be announcing 10 new low emission bus zones, including one for Brixton Road. “But this is not enough,” said the spokesman. “The government needs to match the Mayor’s commitment to improving air quality as quickly as possible.” Penny Woods, chief executive of the British Lung Foundation, said the early breach in Brixton was shocking: “This shows the extent of the public health crisis we are facing. The mix of these toxic air pollution levels with freezing temperatures pose a serious risk to people with lung conditions and can affect all of our health.” Over 60% of the 97 air pollution monitoring sites in London broke legal annual limits in 2016, according to preliminary data from Kings College London seen by the Guardian. Putney High Street, where high buildings trap pollution, was the worst. Its annual average for last year was 125 micrograms of NO2 per cubic metre, over three times the limit of 40µg/m3. Brixton Road recorded 117µg/m3 and Marylebone Road was more than double the limit. The Kings College data also shows Putney High Street broke hourly limits 1,221 times in 2016, vastly exceeding the permitted 18 breaches. Brixton Road broke the hourly limit 502 times. Across the UK, 169 local authorities - 40% - suffered illegally high NO2 air pollution in 2015. This was down from 194 in 2013, but illegal levels of the toxic gas remain a serious issue, with the government estimating it causes 23,500 early deaths a year. In November, data from the European Environment Agency revealed the UK is second only to Italy in Europe for the highest number of annual deaths from NO2. It also ranked London’s Marylebone High Street as the most polluted site in Europe. The government must produce a new draft national plan by April and ClientEarth said this must include clean air zones in many areas to stop the dirtiest diesel cars entering pollution hotspots. ClientEarth also said the “peverse” financial incentives that encourage people to buy diesel cars rather than cleaner ones must be ended. Both a national network of clean air zones and tax changes were proposed within government as part of its last plan, but were rejected by the Treasury. A government spokesperson said: “We are firmly committed to improving the UK’s air quality and cutting harmful emissions. We will update our air quality plans in the spring to further improve the nation’s air quality.” He said the government had committed more than £2bn since 2011 to support ultra-low emissions vehicles and greener transport schemes. In December, Paris, Madrid, Athens and Mexico City pledged to ban polluting diesel cars from their centres by 2025 and a number of cities outside the UK have already taken action such as banning cars on specific days or making public transport free. Jenny Bates, at Friends of the Earth, said: “Air pollution is a major health threat, particularly to children and other vulnerable people. Road traffic is the biggest culprit – and diesel is the worst. This is why the government must take much bolder and quicker action including planning to phase out diesel by 2025.” This week new data also revealed that modern diesel cars produce 10 times more NO2 pollution than heavy trucks and buses per litre of fuel, which experts say is due to the much tougher testing faced by heavy vehicles.
News Article | February 28, 2017
WASHINGTON, D.C., Feb. 28, 2017 -- Limitations of the piezoelectric array technologies conventionally used for ultrasonics inspired a group of University College London researchers to explore an alternative mechanism for generating ultrasound via light, also known as the photoacoustic effect. Coupling this with 3-D printing, the group was able to generate sounds fields with specific shapes for potential use in biological cell manipulation and drug delivery. Piezoelectric materials generate mechanical stress in response to an applied electric field, resulting in a usable and precisely controllable force that can, for example, be used to create sound waves. But achieving this control with conventional piezoelectric arrays requires both complicated electronics and large numbers of extremely small individual components which are expensive and difficult to manufacture. The photoacoustic effect, in contrast, occurs when a short pulse or modulated source of light is absorbed by a material, producing a sound wave. As the group reports in this week's Applied Physics Letters, from AIP Publishing, their work focuses on using the photoacoustic effect to control ultrasound fields in 3-D. "One useful feature of the photoacoustic effect is that the initial shape of the sound that's generated is determined [by] where the light is absorbed," said Michael Brown, a doctoral student at the Biomedical Ultrasound Group of the Department of Medical Physics and Biomedical Engineering at University College London. "This can be used to create tightly focused intense points of sound just by depositing an optical absorber on a concave surface, which acts like a lens." More generally, it's possible to manufacture samples with nearly any surface shape by using a 3-D printer and a transparent material. "By depositing an optical absorber on this surface, which can be done via spray painting, a sound wave of nearly any shape can be created by illuminating this sample with a laser," Brown said. "If you carefully tailor the design of the surface and therefore the shape of the acoustic wave, it's possible to control where the sound field will focus and even create fields focused over continuous shapes. We're using letters and numbers." This is particularly significant because, in theory, the ability to control the shape of the wavefront -- the surface over which the sound wave has a constant phase, somewhat like the edge of the wave -- enables a large degree of control over the resulting field. "But actually designing a wavefront that generates a desired pattern becomes more challenging as the complexity of the target increases," Brown said. "A clear 'best' design is only available for a few select cases, such as the generation of a single focus." To overcome this limitation, the group "developed an algorithm that allows users to input a desired sound field in 3-D, and it then outputs a 3-D printable surface profile that generates this field," Brown said. "Our algorithm allows for precise control of the intensity of sound at different locations and the time at which the sound arrives, making it quick and easy to design surfaces or 'lenses' for a desired application." Brown and his colleagues demonstrated the effectiveness of their algorithm by creating a lens designed to generate a sound field shaped like the numeral 7. After illuminating the lens by a pulsed laser, they recorded the sound field and the desired "7" was clearly visible with high contrast. "It was the first demonstration of generating a multi-focal distribution of sound using this approach," Brown said. There are many potential uses for the tailored optoacoustic profiles created by the group. "Highly intense sound can cause heating or exert forces on objects, such as in acoustic tweezers," Brown said. "And similar single-focus devices are already being used for cleaving cell clusters and targeted drug delivery, so our work could be useful within that area." The group is also interested in the effects of propagating through tissue, which introduces distortions to the shape of wavefronts caused by variations in the speed of sound. "If the structure of the tissue is known beforehand via imaging, our approach can be used to correct for these aberrations," Brown said. "Manipulating the shape and time during which the focused sound is generated can also be useful for the maneuvering and controlling biological cells and other particles." Going forward, Brown and his group hope to investigate the use of other light sources and what advantages they might offer. "One limitation of our work was the use of a single-pulsed laser," Brown said. "This meant that the temporal shape of the sound generated from the sample was only one short pulse, which limited the complexity of the fields that could be generated. In the future, we're interested in using alternative modulated optical sources to illuminate these devices." The article, "Generating arbitrary ultrasound fields with tailored optoacoustic surface profiles," is authored by Michael Brown, Daniil Nikitichev, Bradley E. Treeby and Ben Cox. The article will appear in the journal Applied Physics Letters Feb. 28, 2017 (DOI: 10.1063/1.4976942). After that date, it can be accessed at http://aip. . Applied Physics Letters features concise, rapid reports on significant new findings in applied physics. The journal covers new experimental and theoretical research on applications of physics phenomena related to all branches of science, engineering, and modern technology. See http://apl. .
News Article | February 27, 2017
Harwell Campus SWINDON, 27-Feb-2017 — /EuropaWire/ — A major new £100 million investment by the government into the development of an innovative multi-disciplinary science and technology research centre was announced today (Thursday 23 February 2017) by Business Secretary Greg Clark. The new Rosalind Franklin Institute (RFI) – named in honour of the pioneering British scientist whose use of X-rays to study biological structures played a crucial role in the discovery of DNA‘s ‘double helix’ structure by Francis Crick and James Watson – will bring together UK strengths in the physical sciences, engineering and life sciences to create a national centre of excellence in technology development and innovation. The new Rosalind Franklin Institute will have a hub based at the Harwell campus It will bring together UK expertise to develop new technologies that will transform our understanding of disease and speed up the development of new treatments Part of the government’s Industrial Strategy to maintain the UK’s global leadership in science, innovation and research Business Secretary Greg Clark said: The UK has always been a pioneer in the world of science, technology and medical research. It’s this excellence we want to continue to build on and why we made science and research a central part of our Industrial Strategy – strengthening links between research and industry, ensuring more home-grown innovation continues to benefit millions around the world. Named after one of the UK’s leading chemists, the new Rosalind Franklin Institute will inspire and house scientists who could be responsible for the next great discovery that will maintain the UK’s position at the forefront of global science for years to come. Delivered and managed by the Engineering and Physical Sciences Research Council (EPSRC), the RFI will bring together academic and industry researchers from across the UK to develop disruptive new technologies designed to tackle major challenges in health and life sciences, accelerate the discovery of new treatments for chronic diseases affecting millions of people around the world (such as dementia), and deliver new jobs and long-term growth to the local and UK economies. Chair of the Research Councils and EPSRC Chief Executive, Professor Philip Nelson said: The UK is currently in a world leading position when it comes to developing new medical treatments and technologies in the life sciences. However, other countries are alive to the potential and are already investing heavily. The Rosalind Franklin Institute will help secure the country as one of the best places in the world to research, discover, and innovate. The central hub at Harwell will link to partner sites at the universities of Cambridge, Edinburgh, Manchester and Oxford, Imperial College, King’s College London, and University College London. Industry partners will be on board from the outset, and the Institute will grow over time, as more universities and researchers participate. The work at new Institute will contribute directly to the delivery of EPSRC‘s ‘Healthy Nation’ prosperity outcome, its Healthcare Technologies programme, and to the Technology Touching Life initiative that spans three research councils (the Biotechnology and Biological Sciences Research Council (BBSRC), the Medical Research Council (MRC) and EPSRC) and seeks to foster interdisciplinary technology development research across the engineering, physical and life sciences. The development of the RFI has been led by Professor Ian Walmsley, FRS, from the University of Oxford, who said: This is a new joint venture between some of the UK’s leading universities and key partners in industry and research councils. The aim is to speed the application of cutting-edge physical science insights, methods and techniques to health and life sciences by providing an interface between research programmes at the forefront of these areas, co-located at Harwell and connected, dynamically, to the wider UK research base. We anticipate innovative new businesses will grow from this effort over time, as the Institute will engage with a range of key industries from inception. A collaborative joint venture model allows the RFI to make the most of interactions and draw on a wide range of existing research excellence from across the UK. Patrick Vallance, President of R&D at GSK said: We welcome the creation of the RFI which will bring world-leading, multi-disciplinary teams from industry and academia closer together, and will further strengthen the UK as a place to translate excellent science into patient benefit. Through collaboration we will be able to make advances in life science technologies much quicker than we could manage alone. Research at the RFI will initially be centred on five selected technology themes, focusing on next-generation imaging technologies – X-ray science, correlated imaging (combining X-ray, electron and light microscopy), imaging by sound and light, and biological mass spectrometry – and on new chemical methods and strategies for drug discovery. Dame Carol Robinson, FRS, who is leading the RFI‘s biological mass spectrometry theme, and received the 2004 Royal Society Rosalind Franklin Award that recognises outstanding scientific contributions and supports the promotion of women in science, technology, engineering and mathematics, said: It is fitting that this new Institute bears Rosalind Franklin’s name. She achieved so much in a relatively short life and without her work many of the advances that have taken place since would not have come about. Work in the Institute will include development of the next-generation of physical tools including mass spectrometry, instruments for X-ray science and for advanced microscopy – fields directly descended from her research interests. Notes for Editors: The Engineering and Physical Sciences Research Council (EPSRC) As the main funding agency for engineering and physical sciences research, our vision is for the UK to be the best place in the world to Research, Discover and Innovate. By investing £800 million a year in research and postgraduate training, we are building the knowledge and skills base needed to address the scientific and technological challenges facing the nation. Our portfolio covers a vast range of fields from healthcare technologies to structural engineering, manufacturing to mathematics, advanced materials to chemistry. The research we fund has impact across all sectors. It provides a platform for future economic development in the UK and improvements for everyone’s health, lifestyle and culture. We work collectively with our partners and other Research Councils on issues of common concern via Research Councils UK. The Science and Technology Facilities Council (STFC) STFC is keeping the UK at the forefront of international science and tackling some of the most significant challenges facing society such as meeting our future energy needs, monitoring and understanding climate change, and global security. The Council has a broad science portfolio and works with the academic and industrial communities to share its expertise in materials science, space and ground-based astronomy technologies, laser science, microelectronics, wafer scale manufacturing, particle and nuclear physics, alternative energy production, radio communications and radar. STFC operates or hosts world class experimental facilities including in the UK the ISIS pulsed neutron source, the Central Laser Facility, and LOFAR, and is also the majority shareholder in Diamond Light Source Ltd. It enables UK researchers to access leading international science facilities by funding membership of international bodies including European Laboratory for Particle Physics (CERN), the Institut Laue Langevin (ILL), European Synchrotron Radiation Facility (ESRF) and the European Southern Observatory (ESO). STFC is one of seven publicly-funded research councils. It is an independent, non-departmental public body of the Department for Business, Energy and Industrial Strategy (BEIS). The Biotechnology and Biological Sciences Research Council (BBSRC) BBSRC invests in world-class bioscience research and training on behalf of the UK public. Our aim is to further scientific knowledge, to promote economic growth, wealth and job creation and to improve quality of life in the UK and beyond. Funded by Government, BBSRC invested £473M in world-class bioscience, people and research infrastructure in 2015-16. We support research and training in universities and strategically funded institutes. BBSRC research and the people we fund are helping society to meet major challenges, including food security, green energy and healthier, longer lives. Our investments underpin important UK economic sectors, such as farming, food, industrial biotechnology and pharmaceuticals. More information about BBSRC strategically funded institutes. The Medical Research Council (MRC) The Medical Research Council is at the forefront of scientific discovery to improve human health. Founded in 1913 to tackle tuberculosis, the MRC now invests taxpayers’ money in some of the best medical research in the world across every area of health. Thirty-one MRC-funded researchers have won Nobel prizes in a wide range of disciplines, and MRC scientists have been behind such diverse discoveries as vitamins, the structure of DNA and the link between smoking and cancer, as well as achievements such as pioneering the use of randomised controlled trials, the invention of MRI scanning, and the development of a group of antibodies used in the making of some of the most successful drugs ever developed. Today, MRC-funded scientists tackle some of the greatest health problems facing humanity in the 21st century, from the rising tide of chronic diseases associated with ageing to the threats posed by rapidly mutating micro-organisms. www.mrc.ac.uk Diamond Light Source Diamond Light Source is the UK’s synchrotron science facility, and is approximately the size of Wembley Stadium. It works like a giant microscope, harnessing the power of electrons to produce bright light that scientists can use to study anything from fossils to jet engines to viruses and vaccines. Diamond is used by thousands of academic and industrial researchers across a wide range of disciplines, including structural biology, health and medicine, solid-state physics, materials & magnetism, nanoscience, electronics, earth & environmental sciences, chemistry, cultural heritage, energy and engineering. Many everyday commodities that we take for granted, from food manufacturing to consumer products, from revolutionary drugs to surgical tools, from computers to mobile phones, have all been developed or improved using synchrotron light. Diamond generates extremely intense pin-point beams of synchrotron light. These are of exceptional quality, and range from X-rays to ultraviolet to infrared. Diamond’s X-rays are around 10 billion times brighter than the sun. Diamond is one of the most advanced scientific facilities in the world, and its pioneering capabilities are helping to keep the UK at the forefront of scientific research. 2017 marks a double celebration for Diamond – 15 years since the company was formed, and 10 years of research and innovation. In this time, researchers who have obtained their data at Diamond have authored over 5,000 papers. The institute is funded by the UK Government through the Science and Technology Facilities Council (STFC), and by the Wellcome Trust The Harwell Campus Harwell Campus is a public private partnership between Harwell Oxford Partners, U+I Group PLC and two Government backed agencies, the Science and Technology Facilities Council (STFC) and the UK Atomic Energy Agency (UKAEA). Harwell is one of the world’s most important science and innovation locations. It has a growing reputation as the UK’s gateway to space with over 65 space and satellite applications related organisations located on campus and is now seeing rapid growth in the Life Sciences and HealthTec sector with over 1,000 people working in this field alone at Harwell. In addition to space and life sciences, the campus hosts an array of other key sectors including, Big Data and Supercomputing, Energy and Environment and Advanced Engineering and Materials. With a legacy of many world firsts, the campus comprises 710 acres, over 200 organisations and 5,500 people. Harwell Campus is the UK’s National Science Facility and is among Europe and the world’s leading sites dedicated to the advancement of science, technology and innovation. Having spent 75 years at the forefront of British innovation and discovery, Harwell Campus continues to drive scientific advancements to the benefit of the UK economy and centred around a community hub. Science experts, academics, government organisations, private sector R&D departments and investors create an environment where innovation, collaboration and discovery thrive. Harwell’s Cluster Strategy The Cluster of about 70 Space organisations at Harwell is testament to the power of co-locating industry, academia and the public sector alongside investors and entrepreneurs. The European Space Agency, RAL Space, The UK Space Agency, Airbus, Thales Alenia Space, Lockheed Martin, and Deimos Space UK can all be found on the Campus. This creates many opportunities for collaboration, increasing capability and sharing risk. Being within a Cluster brings access to high-quality common infrastructure, facilities and expertise, alongside exposure to new markets The Harwell vision is to be home to a number of Clusters that exploit the existing strengths of the Campus. The next step is a new HealthTec Cluster that will benefit from the considerable synergies across the life and physical sciences capabilities of the Campus and the Space cluster. These clusters will enrich each other, creating a powerful multidisciplinary environment tailored to problem solving that will allow the UK to compete with the best in the world. The clustering of industries, facilities and science experts has given rise to the term Harwell Effect – and is an ideal model for future science and business innovation programmes. Science clusters drive economic growth. MIT has created businesses with a combined value of $3tn, the equivalent of California’s GDP. Harwell Campus is the only location in the UK with the potential to emulate this success. To find out more about events, open days or the new developments, visit the Harwell Campus website. SOURCE: EPSRC Contact Details In the following table, contact information relevant to the page. The first column is for visual reference only. Data is in the right column. Name: EPSRC Press Office Telephone: 01793 444404
News Article | March 2, 2017
SAN RAMON, CA--(Marketwired - March 02, 2017) - WANdisco ( : WAND), the world leader in Active Data Replication™, is pleased to announce it is supporting a major European project, led by the University of Sheffield, which could make it easier for doctors to spot the early signs of dementia. The Dementia Research Enabled by IT project, VPH-DARE@IT, seeks to learn more about the interaction of genetic, non-genetic and environmental factors thought to cause dementia through the analysis of large quantities of behavioral, genetic, environmental and clinical data. The project is using WANdisco's patented Fusion technology to move large volumes of continuously changing structured and unstructured data between eight different cloud providers so it can be analyzed by more than 950 applications. The researchers hope to be able to combine this data with novel biomarkers to provide new and feasible ways to screen for dementia before symptoms appear. Professor Alex Frangi, lead project coordinator, said, "This project wouldn't be possible without moving around large volumes of continually changing data. We need to do this in a distributed manner and for that we are using cloud technology and WANdisco Fusion. There is no other solution on the market that can move such active data and do it with guaranteed consistency." David Richards, CEO and Co-founder of WANdisco, said, "We have the only solution in the world that can move active data to the cloud with no interruption to service so that data can be analyzed very quickly. It is great to see our technology being used in projects which could make a positive difference to people lives." To learn more about the project please watch our video here. About WANdisco WANdisco is the world leader in Active Data Replication™. Its patented WANdisco Fusion technology enables the replication of continuously changing data to the cloud and on-premises data centers with guaranteed consistency, no downtime and no business disruption. It also allows distributed development teams to collaborate as if they are all working in one location. WANdisco has an OEM with IBM as well as partnerships with Amazon Web Services, Cisco, Google Cloud, Hewlett Packard Enterprise, Microsoft Azure, and Oracle. We also work directly with Fortune 1000 companies around the world to ensure their data gives them the real insight they need. About VPH-DARE@IT The Dementia Research Enabled by IT project -- VPH-DARE@IT -- is a Virtual Physiological Human initiative funded through the European Union. There are a total of 20 partners including from the UK The University of Sheffield, Sheffield Teaching Hospitals Foundation Trust, The University of Oxford, University College London, Imperial College London, Kings' College London. Also involved are companies and research establishments from Finland, France, Germany, Norway, The Netherlands, Switzerland, Portugal and Austria. For more information www.vph-dare.eu About University of Sheffield Center for Computational Imaging and Simulation Technologies in Biomedicine CISTIB is an international and interdisciplinary research center in department of Electronic and Electrical Engineering at the University of Sheffield. It focuses on the development of computational medical imaging. and simulation techniques, with emphasis on angiology, cardiology, neurology and orthopedics. The group's main objective is the consolidation of a solid scientific base regarding the acquisition, analysis, and post processing of medical images and simulations. For more information www.cistib.org
News Article | March 2, 2017
- Cydar announces the appointment of Lord Davies of Abersoch as Chairman, Dr Franz B. Humer and James Downing as Non-Executive Directors - Professor John E. Deanfield to head a new Scientific and Technology Advisory Board - First US installation at Major U.S. Academic Medical Center Cydar Limited ("the Company"), a world leading cloud based surgical guidance software company, announces the appointment of a new Non-Executive Chairman and new Non-Executive Directors. Lord Davies of Abersoch has been appointed Non-Executive Chairman. Dr Franz B. Humer and James B. Downing join the Board as Non-Executive Directors. Professor John Deanfield, will head a new Scientific and Technology Advisory Board. Cydar is the first company in the world using high performance cloud computing to provide surgical guidance in the operating room. At its core, fully-automatic computer vision tracks patients during X-ray guided surgery; enabling it to combine diagnostic scans, planning information and real-time imaging with millimetre precision. "I am delighted to join Cydar as Non-Executive Chairman. The UK is a recognised leader in knowledge based industries, and commercialising British Science is a key driver for long term economic growth. Cydar represents an opportunity for the digital revolution in medicine to help break through the intelligence barrier and generate evidence based improvements for better healthcare outcomes. I look forward to working with the Board and Executives to ensure Cydar has the right strategy and human capital, to help build an innovative, global company to achieve its great potential." "Our successful transition from early-stage to growth company is testament to the efforts of our original Board and outgoing Non-Executive Chairman Mark Evans, who remains as a Non-Executive Director. We believe the skills and experience that Lord Davies, Dr Franz Humer, Jim Downing and Prof John Deanfield now bring will prove invaluable as we pursue our commercial and technology aspirations to be a world leader in cloud based surgical guidance software." First US Luminary Site at Duke University Hospital The Company also announces that it has signed its first US contract with the prestigious Duke University Hospital. This marks the Company's strategic decision to open a US gateway for its first FDA-cleared product, Cydar EV, and to pre-launch its US commercialisation strategy whilst it continues to develop its next clinical indications. Cynthia K. Shortell, M.D. Professor and Chief, Division of Vascular Surgery. Acting Chief, Division of Trauma and Critical Care Surgery. Chief of Staff, Department of Surgery, Duke University Medical Center, commented: "Data from the clinical trials that supported the product's approval suggest it has the potential to be a significant advance in image-guided surgery. We look forward to the opportunity to gain experience with this exciting new technology." "We are delighted to be working with Duke and Professor Cynthia Shortell. Duke is a key luminary site for us and this is an invaluable gate-opening and validation of our Software as a Service offering". "The contract with Duke is the culmination of our efforts to establish a US presence. Installation and onboarding there represents the completion of a comprehensive evaluation process, which included IT, information security, operating room, data sharing and business approvals. We now have significant interest in our product from US physicians and hospitals alike and I expect Duke to act as springboard for our US launch in March." Lord Mervyn Davies brings commercial and international experience to the Board as both a former CEO and Chairman of Standard Chartered Bank, former Minister for Trade, Investment, Small Business and Infrastructure and as current Chairman of Corsair Capital and a Director across a diverse range of companies. Dr Franz B. Humer brings a wealth of healthcare and commercialisation experience as well as deep insights into clinical applications and health data. He is former CEO and Chairman of Roche Plc, having previously been at Glaxo and Schering Plough. James Downing brings extensive deal structuring and negotiating skills as a corporate finance specialist, and former Deputy Head of European Investment Banking at JP Morgan Chase & Co and currently as Non-Executive Director on a number of companies. Professor Deanfield brings expertise in cardiovascular imaging, large-scale clinical trials and outcomes research, both nationally and internationally. He is Professor of Cardiology at University College London and Director of the National Institute for Cardiovascular Outcomes Research (NICOR). Cydar Ltd is a private UK company established in 2012, originally a spin out from Kings College London and Guys & St Thomas' NHS trust. It has successfully completed clinical trials to gain CE Mark and FDA Clearance for its first product - Cydar EV - in 2016 and is currently being used in several UK hospitals, including The Royal Free Hospital and at Guys & St Thomas's Hospital, in London. Cydar Inc (US) is a wholly-owned subsidiary of Cydar Ltd.
News Article | February 24, 2017
Together with university research partner King's College London, Ericsson (NASDAQ: ERIC) and BT have signed a multi-year collaboration agreement on 5G testing and development. King's College contributes with low-latency use cases and specialized knowledge in communication technologies, robotics and haptic control. The collaboration will focus on creating 5G use cases in commercial and consumer markets, with particular focus on mission-critical services such as medical applications. It will involve research into the technical and economic aspects of key 5G-enabling technologies. With the ambition to be first to market with 5G services in the UK, BT has worked with Ericsson to build a 5G Proof of Concept Center at the BT Labs in Adastral Park, Ipswich. With access to the 5G for Europe core network - linking multiple centers and universities across Europe - Ericsson and BT are testing the network architecture needed to most efficiently deliver commercial 5G services. Howard Watson, CEO, BT Technology, Service & Operations, and BT Group CIO, says: "The initial focus of the collaboration is on Proof of Concept solutions and trials of services needing both high availability and low latency - both key features of the forthcoming 5G technology." In 2016, BT bought EE, the United Kingdom's leading 4G network provider. Together, we have the opportunity to build on our existing infrastructure to create a truly converged fixed and mobile network. We look forward to working with Ericsson and Kings College London as we examine the possibilities of 5G, and what it can deliver in terms of flexibility, scalability and the high bandwidths that our customers will require in the future." Anders Lindblad, Senior Vice President and Head of Business Unit IT & Cloud Products, says:"5G is the foundation for expanding the potential to all Industries. The cooperation with BT to trial services using 5G technology demonstrates Ericsson's commitment to drive market demand and adoption. By establishing network slices in the context of 5G will be like virtual networks on-demand, and will be crucial for the mission-critical services being trialed." A demonstration of these capabilities will be on display outside Ericsson's Hall 2 at Mobile World Congress. BT's purpose is to use the power of communications to make a better world. It is one of the world's leading providers of communications services and solutions, serving customers in 180 countries. Its principal activities include the provision of networked IT services globally; local, national and international telecommunications services to its customers for use at home, at work and on the move; broadband, TV and internet products and services; and converged fixed-mobile products and services. BT consists of six customer-facing lines of business: Consumer, EE, Business and Public Sector, Global Services, Wholesale and Ventures, and Openreach. For the year ended 31 March 2016, BT Group's reported revenue was £19,042m with reported profit before taxation of £3,029m. British Telecommunications plc (BT) is a wholly-owned subsidiary of BT Group plc and encompasses virtually all businesses and assets of the BT Group. BT Group plc is listed on stock exchanges in London and New York. Anything can happen on the digital frontier, a promising but undiscovered future. From February 27 to March 2 in Barcelona, Spain, Ericsson is demonstrating a collaborative approach and innovative solutions to succeed in this arena. With our customers and partners, we work across industries, physical boundaries and perceived limitations. Join us in Hall 2 or online during MWC 2017 and engage in conversations and demonstrations about our favorite things: 5G; platforms and services for IT, Cloud, Networks and TV & Media; connected solutions for industries; the Internet of Things; and partnering for success. See you there! Ericsson is a world leader in communications technology and services with headquarters in Stockholm, Sweden. Our organization consists of more than 111,000 experts who provide customers in 180 countries with innovative solutions and services. Together we are building a more connected future where anyone and any industry is empowered to reach their full potential. Net sales in 2016 were SEK 222.6 billion (USD 24.5 billion). The Ericsson stock is listed on Nasdaq Stockholm and on NASDAQ in New York. Read more on www.ericsson.com.
News Article | February 16, 2017
The discovery of the 'molecular switch' that causes inflammatory bowel disease (IBD) and Celiac disease, could lead to more effective new treatments for these life-changing auto-immune conditions, according to research from scientists at King's College London and University College London. For the first time, researchers have a specific target for the treatment of these conditions by identifying an immune molecule called T-bet as the key control point that regulates this genetic risk in specific diseases. The discovery has been published in the journal PLoS Genetics. T-bet plays an important role in coordinating the body's immune responses. In patients with IBD, T-bet behaves abnormally, causing the immune reaction which leads to the development of the condition. A great deal of work has been done on the genetic predisposition to autoimmune disease over the past 10 years. However, it has been very difficult to develop effective treatments because a large number of genes each make a very small contribution to the development of these diseases. "Our research outlines a specific focus for the development of new treatments for these diseases which have such a profound effect on sufferers," said Graham Lord, co-senior author on the study and firector of the National Institute for Health Research Biomedical Research Centre.
News Article | March 2, 2017
INmune Bio, Inc., a cancer immunotherapy company focused on developing therapies that prime natural killer (NK) cells to attack cancer, today announces that its co-founder, Professor Mark Lowdell, PhD, FRCPath FRSB, has been named one of Europe's 10 academic-entrepreneur superstars by Labiotech, the leading digital media covering the European Biotech industry. "I was surprised and delighted to be named one of the elite academic-entrepreneurs in this field in Europe. I have been fortunate to be able to work alongside academic and commercial collaborators to develop a number of scientific discoveries that have the prospect of becoming successful therapies able to make a difference in the lives of patients," states Professor Lowdell. Professor Lowdell is the Professor of Cell & Tissue Therapy and Director of the Centre for Cell, Gene & Tissue Therapy at the Royal Free London NHS FT and University College London. He is an established leader in the development of cell and tissue medicines for immunotherapy and regenerative medicine and has been responsible for the development and delivery of multiple cell-based therapies both academically and commercially. In addition to being a co-founder of INmune Bio, Professor Lowdell is also the Company's Chief Scientific Officer and chair of the Scientific Advisory Board. Professor Lowdell is also a founder-shareholder of CellMedica Ltd. and a member of its scientific advisory board. In 2016 he became a co-founder of Achilles Therapeutics, an immunotherapy company funded by Syncona, the venture fund of the Wellcome Trust. He is a consultant to multiple biopharma companies and contract manufacturers across the field of cell and tissue therapy. Professor Lowdell holds a PhD in clinical immunology from the University of London and fellowships from the Royal College of Pathologists (immunopathology) and the Royal Society of Biology. He is the current vice president (EU- Middle East) of the International Society for Cell Therapy. Dr. RJ Tesi, MD, CEO and co-founder of INmune Bio, commented, "Mark has a rare combination of having the intellect of a consummate academic scientist as well as the knowledge of a successful entrepreneur when he looks at the practical, regulatory and technical challenges of delivering and then commercializing novel therapies from the lab bench. All of us at INmune Bio look forward to his continued insight, innovation and experience." INmune Bio's lead candidate is INKmune™, a novel biologic therapy that primes the patient's NK cells to attack their cancer. In pre-clinical studies, INKmune has been shown to attack many types of hematologic malignancies including leukemia, lymphoma, multiple myeloma and epithelial cancers including breast, ovarian, prostate, renal and lung cancer. INmune expects to begin clinical trials of INKmune™ by year-end 2017. INmune Bio is a private clinical stage biotechnology company developing therapies for targeting the innate immune system. INmune Bio is developing INKmune™, a novel therapy that harnesses the patient's own NK cells to attack their cancer. INmune is targeting residual disease - the cancer cells that survive initial treatments that return to cause the cancer relapse which may cause death. Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells' ability to eliminate residual disease. Labiotech is the leading digital media covering the European Biotech industry. Over 70,000 people use it monthly to keep a watch on the business and innovations of biotechnologies. Forward-looking statements: This press release contains certain "forward-looking statements." Such statements may include statements relating the leadership of the company and other statements relating to future events or to the company's future financial performance and are not historical facts, including statements which may be preceded by the words "intends," "may," "will," "plans," "expects,” "anticipates," “projects," "predicts," "estimates," "aims,” "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the company. Actual results may differ materially from the expectations contained in the forward-looking statements. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's Private Placement Memorandum. The company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
News Article | February 17, 2017
A study by researchers at the University of Southampton shows that antibiotics may be an effective treatment for acute non-complicated appendicitis in children, instead of surgery. The systematic review of existing literature is published in Pediatrics. The condition, which causes the appendix -- a small organ attached to the large intestine -- to become inflamed due to a blockage or infection, affects mainly children and teenagers. Appendicitis is currently treated through an operation to remove the appendix, known as an appendicectomy, and it is the most common cause of emergency surgery in children. The review, led by Nigel Hall, Associate Professor of Paediatric Surgery at the University of Southampton, assessed existing literature published over the past 10 years that included 10 studies reporting on 413 children who received non-operative treatment rather than an appendectomy. It shows that no study reported any safety concern or specific adverse events related to non-surgical treatment, although the rate of recurrent appendicitis was 14 per cent. Mr Hall, who is also a Consultant Paediatric and Neonatal Surgeon at Southampton Children's Hospital, commented: "Acute appendicitis is one of the most common general surgical emergencies worldwide and surgery has long been the gold standard of treatment. But it is invasive and costly, not to mention extremely daunting for the child concerned and their family. Our review shows that antibiotics could be an alternative treatment method for children. When we compared the adult literature to the data in our review it suggested that antibiotic treatment of acute appendicitis is at least as effective in children as in adults. This now needs to be explored more widely." The review says that longer term clinical outcomes and cost effectiveness of antibiotics compared to appendicectomy require further evaluation, preferably as large randomised trials to reliably inform decision making. To further this research Mr Hall and his team in Southampton, along with colleagues at St George's Hospital in Tooting, Alder Hey Children's Hospital in Liverpool and Great Ormond Street Hospital, are currently carrying out a year-long feasibility trial which will see children with appendicitis randomly allocated to have either surgery or antibiotic treatment. Mr Hall said: "In our initial trial, we will see how many patients and families are willing to join the study and will look at how well children in the study recover. "This will give us an indication of how many children we may be able to recruit into a future larger trial and how the outcomes of non-operative treatment compare with an operation." The study -- known as CONservative TReatment of Appendicitis in Children a randomised controlled Trial (CONTRACT) -- is being funded through a £483,000 grant from the National Institute for Health Research Health Technology Assessment Programme and co-ordinated by the University of Southampton's clinical trials unit in collaboration with the University of Bristol, the University of Liverpool and University College London.
News Article | January 10, 2017
Researchers discover that experimental Alzheimer's drug causes teeth to regrow tissue lost to cavities A paper from a group of Kings College London researchers documents an unexpected and welcome side effect from an experimental anti-Alzheimer's drug called Tideglusib: test subjects experienced a regeneration of dentin, the bony part of teeth that sits between the pulp and the enamel. The drug stimulates brain-cell regeneration. But when it is applied topically to teeth, it suppressed the release of a kind of tau protein, which allowed them to sprout new stem cells, which led to the replenishment of dentin. The King’s College researchers put the enzyme inhibitor on biodegradable collagen sponges, stuck them in subjects’ teeth where cavities had formed and found they healed up without the need for any drilling or filling. “Using a drug that has already been tested in clinical trials for Alzheimer’s disease provides a real opportunity to get this dental treatment quickly into clinics,” Sharpe said in a release. Promotion of natural tooth repair by small molecule GSK3 antagonists [Vitor C. M. Neves, Rebecca Babb, Dhivya Chandrasekaran & Paul T. Sharpe/Scientific Reports]